Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
jazz · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Jazz Pharmaceuticals plc (JAZZ) measures how much investors pay for each dollar of the company's trailing earnings. JAZZ's current PE ratio of 500.30x is calculated by dividing its stock price of $235.85 by its TTM earnings per share of $0.48. +2312.3% elevated vs 5Y avg 20.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%16.6x
MedianQ3 · 75%167.5x
Max
At 500.30x, JAZZ's current P/E is higher than in 100% of its annual fiscal year readings over the past 13 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Jazz Pharmaceuticals plcYou JAZZ | $14.8B | 500.30x | — | $0.48 |
 Abivax S.A. ABVX | $6.8B | N/A | — | -$4.83 |
 Axsome Therapeutics, Inc. AXSM | $12.3B | N/A | — | -$3.68 |
 Caris Life Sciences, Inc. CAI | $4.7B | N/A | — | -$0.32 |
 Cytokinetics, Incorporated CYTK | $8.7B | N/A | — | -$6.54 |
 Halozyme Therapeutics, Inc. HALO | $8.5B | 25.45x | — | $2.64 |
 Madrigal Pharmaceuticals, Inc. MDGL | $11.0B | N/A | — | -$12.85 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.84 | — | |
2024-12-31 FY2024 | 13.60x | $9.06 | -27.6% | |
2023-12-31 FY2023 | 18.77x | $6.55 | — | |
2022-12-31 FY2022 | — | $-3.58 | — | |
2021-12-31 FY2021 | — | $-5.51 | — | |
2020-12-31 FY2020 | 38.54x | $4.28 | +138.1% | |
2019-12-31 FY2019 | 16.19x | $9.22 | -2.7% | |
2018-12-31 FY2018 | 16.63x | $7.45 | +0.4% | |
2017-12-31 FY2017 | 16.57x | $8.13 | -0.3% | |
2016-12-31 FY2016 | 16.62x | $6.56 | -36.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Jazz Pharmaceuticals plc (JAZZ) measures how much investors pay for each dollar of the company's trailing earnings. JAZZ's current PE ratio of 500.30x is calculated by dividing its stock price of $235.85 by its TTM earnings per share of $0.48.
Frequently asked questions
JAZZ pe ratio · 6 questionsJAZZ's current PE ratio is 500.30x as of 2026-06-08, based on a stock price of $235.85 and TTM EPS of $0.48. Data sourced from Financial Modeling Prep via JAZZ's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Jazz Pharmaceuticals plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08